Literature DB >> 24357332

T cell avidity and tumor immunity: problems and solutions.

Arthur A Hurwitz1, Steven M Cuss, Katherine E Stagliano, Ziqiang Zhu.   

Abstract

A potent T cell response is an important component of durable anti-tumor immunity. The quality of the T cell response can, in-part, be measured by the avidity of the T cell for its tumor antigen-expressing target. While convention suggests that raising the avidity of the responding T cells may make for a more potent anti-tumor immune response, the threshold for effective tumor immunity remains unclear, as do some of the adverse effects of an inappropriately high avidity response. In this review, we discuss the relationship between T cell avidity and anti-tumor immunity, considering both experimental model systems as well as human clinical trials.

Entities:  

Year:  2013        PMID: 24357332      PMCID: PMC4150879          DOI: 10.1007/s12307-013-0143-1

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  77 in total

1.  Dynamic in situ cytometry uncovers T cell receptor signaling during immunological synapses and kinapses in vivo.

Authors:  Hélène D Moreau; Fabrice Lemaître; Emmanuel Terriac; Georges Azar; Matthieu Piel; Ana-Maria Lennon-Dumenil; Philippe Bousso
Journal:  Immunity       Date:  2012-06-07       Impact factor: 31.745

2.  Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.

Authors:  Daphné A Schmid; Melita B Irving; Vilmos Posevitz; Michael Hebeisen; Anita Posevitz-Fejfar; J-C Floyd Sarria; Raquel Gomez-Eerland; Margot Thome; Ton N M Schumacher; Pedro Romero; Daniel E Speiser; Vincent Zoete; Olivier Michielin; Nathalie Rufer
Journal:  J Immunol       Date:  2010-03-29       Impact factor: 5.422

3.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

4.  Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.

Authors:  Virna Marin; Elisabetta Cribioli; Brian Philip; Sarah Tettamanti; Irene Pizzitola; Andrea Biondi; Ettore Biagi; Martin Pule
Journal:  Hum Gene Ther Methods       Date:  2012-12       Impact factor: 2.396

5.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

6.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

7.  Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

Authors:  Paul F Robbins; Yong F Li; Mona El-Gamil; Yangbing Zhao; Jennifer A Wargo; Zhili Zheng; Hui Xu; Richard A Morgan; Steven A Feldman; Laura A Johnson; Alan D Bennett; Steven M Dunn; Tara M Mahon; Bent K Jakobsen; Steven A Rosenberg
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

8.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

9.  Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.

Authors:  Claire N Janicki; S Rhiannon Jenkinson; Neil A Williams; David J Morgan
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Authors:  H J Zeh; D Perry-Lalley; M E Dudley; S A Rosenberg; J C Yang
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

View more
  8 in total

Review 1.  To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Authors:  Jessica E Thaxton; Zihai Li
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma.

Authors:  Kalliopi Ioannidou; Olivier Randin; Aikaterini Semilietof; Hélène Maby-El Hajjami; Petra Baumgaertner; Dominique Vanhecke; Daniel E Speiser
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

3.  Potentiating the Antitumor Activity of Cytotoxic T Cells via the Transmembrane Domain of IGSF4 That Increases TCR Avidity.

Authors:  Hye-Ran Kim; Jeong-Su Park; Yasmin Fatima; Maiza Kausar; Jin-Hwa Park; Chang-Duk Jun
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561

4.  Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.

Authors:  Sofie Kirial Mørk; Mohammad Kadivar; Kalijn Fredrike Bol; Arianna Draghi; Marie Christine Wulff Westergaard; Signe Koggersbøl Skadborg; Nana Overgaard; Anders Bundgård Sørensen; Ida Svahn Rasmussen; Lars Vibe Andreasen; Christina Westmose Yde; Thomas Trolle; Christian Garde; Jens Friis-Nielsen; Nis Nørgaard; Dennis Christensen; Jens Vindahl Kringelum; Marco Donia; Sine Reker Hadrup; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2022-01-10       Impact factor: 8.110

Review 5.  Safety and Tolerability of Adoptive Cell Therapy in Cancer.

Authors:  Benita Wolf; Stefan Zimmermann; Caroline Arber; Melita Irving; Lionel Trueb; George Coukos
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.228

6.  Heterogeneity assessment of functional T cell avidity.

Authors:  Kalliopi Ioannidou; Petra Baumgaertner; Philippe O Gannon; Michel F Speiser; Mathilde Allard; Michael Hebeisen; Nathalie Rufer; Daniel E Speiser
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

Review 7.  RNA-electroporated T cells for cancer immunotherapy.

Authors:  Fernanda Pohl-Guimarães; Lan B Hoang-Minh; Duane A Mitchell
Journal:  Oncoimmunology       Date:  2020-10-07       Impact factor: 8.110

8.  Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis.

Authors:  Ashley A Stegelmeier; Jacob P van Vloten; Amanda W K AuYeung; Robert C Mould; Khalil Karimi; J Paul Woods; James J Petrik; Geoffrey A Wood; Byram W Bridle
Journal:  Sci Rep       Date:  2021-07-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.